Andrea Alimonti

Andrea Alimonti
on behalf of
Istituto Oncologico di Ricerca (IOR) USI (Rif. IOR)
is currently participating in the Research Group
Molecular Oncology
as Group Leader [Rif. 55110]

Andrea Alimonti has participated - as a whole - in 30 publications (as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations) - here below are the ones using the term string cancer

1) Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer

2) The potential role of the microbiota in prostate cancer pathogenesis and treatment

3) VSSP-activated macrophages mediate senescence and tumor inhibition in a preclinical model of advanced prostate cancer

4) Targeting PML in triple negative breast cancer elicits growth suppression and senescence

5) Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer

6) Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer

7) Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer

8) B7-H3 as a Therapeutic Target in Advanced Prostate Cancer

9) Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer

10) HER3 Is an Actionable Target in Advanced Prostate Cancer

11) Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis

12) CD38 in Advanced Prostate Cancers

13) Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer

14) Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis

15) CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo.

Andrea Alimonti has participated - as a whole - in 30 publications
(as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations) - here below are the ones using the term string cancer